Vanda Pharmaceuticals (VNDA) Current Deferred Revenue (2009 - 2014)
Vanda Pharmaceuticals recorded quarterly Current Deferred Revenue of $174000.0 in Q4 2014, down 27.8% quarter-over-quarter from $241000.0 in Q3 2014, and down 99.81% year-over-year from $90.3 million in Q4 2013.
Vanda Pharmaceuticals' Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $174000.0 for Q4 2014.
- In Q4 2014, Current Deferred Revenue fell 99.81% year-over-year to $174000.0; the TTM figure through Dec 2014 stood at $174000.0 (down 99.81% YoY), while the FY2014 annual figure was $174000.0, down 99.81% from the prior year.
- Current Deferred Revenue came in at $174000.0 for Q4 2014 at Vanda Pharmaceuticals, down from $241000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $170.6 million in Q4 2010 to a low of $174000.0 in Q4 2014.
- A 5-year average of $89.8 million and a median of $100.4 million in 2013 frame the typical range for Current Deferred Revenue.
- Across the five-year window, Current Deferred Revenue surged 387.4% in 2012 and sank 99.81% in 2014, its largest moves.
- Vanda Pharmaceuticals' Current Deferred Revenue stood at $170.6 million in 2010, then declined by 15.7% to $143.9 million in 2011, then decreased by 18.62% to $117.1 million in 2012, then dropped by 22.88% to $90.3 million in 2013, then tumbled by 99.81% to $174000.0 in 2014.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $174000.0, $241000.0, and $75.1 million for Q4 2014, Q3 2014, and Q2 2014 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 174,000.00 |
| Sep 30, 2014 | 241,000.00 |
| Jun 30, 2014 | 75.06 Mn |
| Mar 31, 2014 | 82.82 Mn |
| Dec 31, 2013 | 90.28 Mn |
| Sep 30, 2013 | 97.03 Mn |
| Jun 30, 2013 | 103.78 Mn |
| Mar 31, 2013 | 110.46 Mn |
| Dec 31, 2012 | 117.06 Mn |
| Sep 30, 2012 | 123.82 Mn |
| Jun 30, 2012 | 130.57 Mn |
| Mar 31, 2012 | 137.25 Mn |
| Dec 31, 2011 | 143.85 Mn |
| Sep 30, 2011 | 26.79 Mn |
| Jun 30, 2011 | 26.79 Mn |
| Dec 31, 2010 | 170.64 Mn |
| Dec 31, 2009 | 197.43 Mn |